These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37675517)

  • 1. Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis.
    Van Laar JAM
    Haematologica; 2024 Feb; 109(2):374-375. PubMed ID: 37675517
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.
    Boonstra PS; Ahmed A; Merrill SA; Wilcox RA
    Am J Hematol; 2021 Apr; 96(4):E103-E105. PubMed ID: 33428805
    [No Abstract]   [Full Text] [Related]  

  • 3. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
    Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
    Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
    Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 6. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
    Trantham T; Auten J; Muluneh B; Van Deventer H
    J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
    Jianguo L; Zhixuan Z; Rong L; Xiaodong S
    Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
    Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
    Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib.
    Marois L; Touzot F; Haddad E; Fernandez I; Morin MP; De Bruycker JJ; Duval M; Cellot S; Teira P; Bittencourt H; Decaluwe H
    Pediatr Blood Cancer; 2021 Jun; 68(6):e28954. PubMed ID: 33694335
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined Use of Emapalumab With Ruxolitinib and Dexamethasone as an Effective Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis Complicated With Multiorgan Damage and Severe Infection.
    Liang J; Xu X; Chen Z; Yu J; Tang Y
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):e360-e362. PubMed ID: 38691058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
    Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.
    Lévy R; Fusaro M; Guerin F; Chetouani A; Moshous D; Fischer A; de Saint Basile G; Sepulveda FE; Neven B
    Blood Adv; 2020 Apr; 4(7):1383-1387. PubMed ID: 32271897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer.
    Portsmore S; Tran Nguyen TN; Beacham E; Neelakantan P
    Br J Haematol; 2020 Aug; 190(4):525-528. PubMed ID: 32584421
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib.
    Song Y; Wang J; Wang X; Wang Y; Wang Z
    Chin Med J (Engl); 2021 May; 135(2):237-239. PubMed ID: 34054023
    [No Abstract]   [Full Text] [Related]  

  • 15. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?
    Liu JM; Chi J
    Exp Biol Med (Maywood); 2022 Feb; 247(4):330-337. PubMed ID: 35068219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis.
    Chi Y; Liu R; Zhou ZX; Shi XD; Ding YC; Li JG
    Pediatr Rheumatol Online J; 2021 Apr; 19(1):49. PubMed ID: 33794928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective.
    Triebwasser MP; Barrett DM; Bassiri H; Bunin N; Elgarten C; Freedman J; Geera AS; Monos D; Lambert MP; Olson T; Seif AE; Paessler M; Petrosa W; Reilly AF; Romberg N; Sullivan KE; Quinn GZ; Behrens E; Teachey DT
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29026. PubMed ID: 33754483
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
    Keenan C; Nichols KE; Albeituni S
    Front Immunol; 2021; 12():614704. PubMed ID: 33664745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience.
    Slostad J; Hoversten P; Haddox CL; Cisak K; Paludo J; Tefferi A
    Am J Hematol; 2018 Feb; 93(2):E47-E49. PubMed ID: 29134683
    [No Abstract]   [Full Text] [Related]  

  • 20. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
    Yan WL; Yang SL; Zhao FY; Xu XJ
    J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.